When it comes to effective mesothelioma treatments, options are unfortunately limited. There is no cure for mesothelioma and first line chemotherapy treatment Alimta, is no guarantee. Many who are suffering from mesothelioma, who have found little or no comfort in traditional treatments, may turn to clinical trials for hope. Through clinical trials, patients have access
Archive for the 'Drug Companies' Category
A Phase III clinical trial is now underway in the pivotal study of interferon alfa-2b gene therapy in pleural mesothelioma. After promising results from the Phase II clinical trial, scientists and researchers are hopeful they are just one step away from FDA approval for this cancer treatment that is over 20 years in the making.
Mesothelioma is a rare cancer affecting only about 3,000 Americans each year. Most of those diagnosed are diagnosed with pleural mesothelioma, but a small number (approx. 500 per year) are diagnosed with peritoneal mesothelioma, which is mesothelioma in the abdominal lining. With so few diagnosed with peritoneal mesothelioma, studying and evaluating the illness has been
The Orphan Drug Act and the National Organization for Rare Disorders Bring Attention and Funding to Rare Diseases
Testing and developing new drugs and treatments for an illness is a costly endeavor, but drug companies thrive in this business by being able to sell medication to the sick – especially those suffering from common conditions. The more common a condition, the more profits drug companies will make selling their product. The more potential
Immunotherapy treatments are becoming known alternatives to chemotherapy in cancer patients who have had little success with traditional cancer treatments. With mesothelioma, often times first line treatments have little effect because the cancer is typically in the advanced stages by the time it is detected. While there currently is no cure for mesothelioma, scientists and
The latest success concerning a treatment for non- small cell lung cancer (NSCLC) has scientists and researchers hopeful that the same treatment can be applied to mesothelioma victims. The Phase III trial for Alecensa (alectinib), while currently not recruiting participants, is on-going and results thus far have shown to be promising for those with NSCLC.
MolMed: NGR-hTNF: increased recruitment rate – with completion foreseen by the end of the year – in the Phase III mesothelioma trial, and new European patent granted
Claudio Bordignon, Chairman of the Board and CEO of MolMed, commented: "The first half-year confirms the positive trend already outlined in the first three months of 2012 in two fields of the Company’s activities. The Phase III trial of NGR-hTNF in mesothelioma recorded a constant increase in the rate of patient recruitment, confirming the forecast
Bayer HealthCare receives Orphan Drug Designation for its Anti-Cancer Agent in the U.S. for the Treatment of Mesothelioma
Bayer HealthCare announced today that its investigational anti-cancer agent BAY 94-9343, a mesothelin-targeting antibody-drug conjugate (ADC), has been granted orphan drug status for the treatment of patients with mesothelioma by the U.S. Food and Drug Administration (FDA). This investigational agent is currently in Phase I clinical development. ‘This is an important step in the development
Raltitrexed (Tomudex®) in Combination With Cisplatin in the Treatment of MPM Improves Overall Survival Compared to Treatment With Cisplatin Alone
Raltitrexed (Tomudex®) in Combination With Cisplatin in the Treatment of MPM Improves Overall Survival Compared to Treatment With Cisplatin Alone1 MPM is a Rare Cancer, but its Incidence is Expected to Double Over the Next 20 Years in Many Countries2 Raltitrexed is Currently Licensed for the Treatment of MPM in Portugal, Czech Republic and Hungary;
MolMed S.p.A. (Milan:MLM) announces the treatment of the first patient in a pivotal Phase III trial (NGR015) of its investigational antitumour drug NGR-hTNF in malignant pleural mesothelioma, a condition linked with repeated exposition to asbestos fibers. Claudio Bordignon, MolMed’s chairman and CEO, comments: “We are really proud of this important milestone, as NGR-hTNF may represent
microRNAs Shown To Have Powerful Potential as Diagnostic and Prognostic Markers In A Variety Of Cancer Indications
Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer Research’s (AACR) 101st Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. from April 17-21, 2010. The posters will include data on
Bionomics, an Australian drug discovery and development company, is set to initiate the second Phase II clinical trial of vascular disrupting agent BNC105 in patients with advanced mesothelioma. Bionomics has already commenced Phase II testing of the anti-cancer properties of BNC105 in renal cancer in the US. The commencement of these two Phase II trials
Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients
Demonstrate potential of miR-29c* to act as an independent prognostic factor for time to progression as well as survival after surgery Ability to forecast outcomes for malignant pleural mesothelioma (MPM) may enable clinicians to provide aggressive therapy to the most appropriate patients Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announced
Rosetta Genomics and Warnex Medical Laboratories Announce Exclusive Distribution Agreement for Rosetta’s microRNA-based Assays in Canada
Rosetta Genomics, Ltd. (NASDQ:ROSG), the leading developer of microRNA-based molecular diagnostics, and Warnex Medical Laboratories, a division of Warnex Inc. (TSX:WNX), announced today they have signed an exclusive distribution agreement in Canada for three currently-available diagnostic tests. Under the terms of the agreement, Warnex will market Rosetta Genomics’ miRview™ tests. Samples will be sent from
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Rosetta Genomics Ltd. (Nasdaq: ROSG), an innovative molecular diagnostic company, today announced the execution of a license and collaboration agreement under which Rosetta shall grant Prometheus U.S. rights to three recently introduced, microRNA-based cancer diagnostic tests: miRview™ mets, miRview™ squamous and miRview™ meso. The terms
Last update: April 01, 2019. 03:30:08 pm.